1. Home
  2. ACTU
  3. ACTU News

Latest ACTUATE THERAPEUTICS INC (ACTU) News on December 25, 2024

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
ACTU

GlobeNewswire

8 days ago

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics to be Added to Russell 2000® Index
ACTU

GlobeNewswire

a month ago

Actuate Therapeutics to be Added to Russell 2000® Index

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma
ACTU

GlobeNewswire

a month ago

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development
ACTU

GlobeNewswire

2 months ago

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor
ACTU

GlobeNewswire

3 months ago

Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor

Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research
ACTU

GlobeNewswire

3 months ago

Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research

Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
ACTU

GlobeNewswire

3 months ago

Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
ACTU

GlobeNewswire

4 months ago

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
ACTU

GlobeNewswire

4 months ago

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024
ACTU

GlobeNewswire

4 months ago

Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024

Actuate Therapeutics Announces Closing of Initial Public Offering
ACTU

GlobeNewswire

4 months ago

Actuate Therapeutics Announces Closing of Initial Public Offering

Share on Social Networks: